Highlights in Acute Lymphoblastic Leukaemia: European Hematology Association (EHA) 2025

IN RECENT YEARS, significant improvements have been achieved in the management of children and adults with either Philadelphia (Ph) chromosome-positive or negative acute lymphoblastic leukaemia (ALL). The most important have been the incorporation of immunotherapy in newly diagnosed patients and the incorporation of new monoclonal antibodies and CAR-T constructs in the treatment of relapsed or refractory (R/R) patients. In Ph-positive ALL, new tyrosine kinase inhibitors (TKI) are being incorporated in first-line treatment, and the role of haematopoietic transplantation is being redefined. On the other hand, advances in T-ALL are still modest, the most promising being the CAR-T use in R/R patients.